Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line
about
Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor VaccinationStructure of the gene of tum- transplantation antigen P198: a point mutation generates a new antigenic peptideThe gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 miceImmunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutationStructure of the gene of tum- transplantation antigen P35B: presence of a point mutation in the antigenic alleleTeratocarcinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line.Tumor cell variants obtained by mutagenesis of a Lewis lung carcinoma cell line: immune rejection by syngeneic miceImmunogenic capacity of tum--variants isolated from a rat rhabdomyosarcomaImmunologic studies of membrane mutants of a highly metastatic murine tumorTreatment of human cell lines with 5-azacytidine may result in profound alterations in clonogenicity and growth rate.Cancer immunoediting by the innate immune system in the absence of adaptive immunity.Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesisImmunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis.Heterogeneity of tumorigenicity phenotype in murine tumors. I. Characterization of regressor and progressor clones isolated from a nonmutagenized ultraviolet regressor tumorMechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells.Leukocyte subpopulations elicited by a nontumorigenic variant of B16 melanoma: their role in direct rejection of the melanoma and in prevention of tumorigenesis in Winn assays.Protection against two spontaneous mouse leukemias conferred by immunogenic variants obtained by mutagenesis.Selection of strongly immunogenic "tum-" variants from tumors at high frequency using 5-azacytidineSelf antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapyDTIC xenogenized lines obtained from an L1210 clone: clonal analysis of cytotoxic T lymphocyte reactivityDecreased tumorigenicity correlates with expression of altered cell surface carbohydrates in Lec9 CHO cells.Tum- antigens, TSTA, and T cell immune surveillance.T cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patients.Tools to define the melanoma-associated immunopeptidome.Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors.Immunotherapy and radiation in glioblastoma.mRNA Cancer Vaccines.Tumor immunotherapy by vaccination with cytokine gene transfected cells.Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice.Autoimmunity and tumor immunity induced by immune responses to mutations in self.Discovery and Subtyping of Neo-Epitope Specific T-Cell Responses for Cancer Immunotherapy: Addressing the Mutanome.Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis
P2860
Q26769044-9C9A460F-C75A-48A0-B765-2A755DD3F182Q33255829-C628AF86-0725-4E0B-B037-CD8BF719E123Q33387226-9361E85C-CD22-47E8-9099-F4CFC0ADCF63Q33564130-D2B8EB4E-3FD2-4E80-B4F4-DB92CA69495AQ33751018-EF238AB0-970E-41F3-951F-9A2AD2C41D2EQ33969318-997B0B32-58BA-4994-91DC-153DA633A9BCQ34038759-187BB719-BAA4-4E02-9BE7-8A1F2811FD3EQ36027890-482EDA05-D42E-403B-BD85-751F17397143Q36093172-191BB9A8-2A46-489A-82A8-498B252664E3Q36211624-22AEBA52-E95F-4C2E-9D03-A25661F27EC7Q36278057-2CECC4A0-697D-4180-8EB4-49E33EB7D8D5Q36306803-BD02F103-2E8A-4CB6-97A2-9863AB0B74AFQ36344171-140821DA-9F32-4147-B431-1EA188AA56DBQ36344772-BD357046-4FEB-4A84-9618-576113C534FEQ36346164-6FAAEE96-8851-4913-B0CB-8CDFC1048303Q36347227-DC86702C-6CAF-4239-B1CA-58C1BC471DFAQ36347974-0D84049A-19FB-4E43-A236-2049A4FD8DAEQ36348769-A39A298D-7821-4F98-9DB9-118622B15B3CQ36380506-59A1EAC2-86B0-4BC9-A8ED-05CF0E40A10AQ36466581-6B55B4BD-1C6E-465B-A333-E1821B08E678Q36912409-D03DE190-F4A1-4080-842D-F9AB6B4F3DDFQ36968849-BEB03142-57BC-4D40-8F0D-83908F5328FAQ38101679-6E5678E3-07AC-49C2-8E01-EE2D3CA5336FQ38650013-BEB6F978-CC6A-44EF-8BB8-189E1A7F64EFQ38730989-2E1CF37C-6AF2-4A2F-ADB5-16AE341FEB70Q38752191-5ACFC53D-45AD-4F7A-A45E-F27496183181Q39013357-2ACD4E52-3312-4D4D-8550-4255CC465142Q41455939-13D65A58-A438-418D-8F68-009301C09C3BQ42935300-829150B4-8EAB-44BB-A70E-9F884E0C9400Q46917393-500886A7-9D62-42A2-8C77-DD71AB9587B3Q51253901-D5735EF6-2EA9-4B5E-A27C-C22B0AA050A2Q58788761-DEF8A245-41AE-43FF-946F-CF8DD4B44269
P2860
Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 1977
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Rejection by syngeneic mice of ...... nant teratocarcinoma cell line
@en
Rejection by syngeneic mice of ...... ant teratocarcinoma cell line.
@nl
type
label
Rejection by syngeneic mice of ...... nant teratocarcinoma cell line
@en
Rejection by syngeneic mice of ...... ant teratocarcinoma cell line.
@nl
prefLabel
Rejection by syngeneic mice of ...... nant teratocarcinoma cell line
@en
Rejection by syngeneic mice of ...... ant teratocarcinoma cell line.
@nl
P2860
P356
P1476
Rejection by syngeneic mice of ...... nant teratocarcinoma cell line
@en
P2093
P2860
P304
P356
10.1073/PNAS.74.1.272
P407
P577
1977-01-01T00:00:00Z